PMA device
Navitor Transcatheter Aortic Valve Implantation System
Abbott Medical · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Jan 13, 2023, newest Oct 29, 2026Aortic stenosis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
10
Naming "Navitor"
MAUDE reports
0
Brand "Navitor", since 2015
PubMed studies
113
Mentioning "Navitor"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Navitor Transcatheter Aortic Valve Implantation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 6 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Navitor", any status and sponsor, newest update first.
- Portico Next Generation Approval StudyActive, not recruiting
Abbott Medical DevicesPublic (ABT)
NCT04011722 · 333 participants · Start Sep 17, 2019 · Primary completion Jan 12, 2023
Device: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System; Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System · For: Symptomatic Severe Aortic Stenosis
Sites: Los Angeles, California; Thousand Oaks, California; Washington D.C., District of Columbia · 28 sites in all
- ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve ImplantationPivotal-lookingEnrolling by invitation
Abbott Medical DevicesPublic (ABT)
NCT05932615 · 1,500 participants (planned) · Start Mar 15, 2024 · Primary completion Apr 2027
Device: Navitor Transcatheter Aortic Valve Implantation (TAVI) System; Any Commercially Available Transcatheter Aortic Valve (CAV) System · For: Aortic Valve Stenosis; Heart Valve Diseases; Aortic Valve Disease and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 107 sites in all
- Balloon- Versus Self-Expanding Intraannular TAVI in Small Aortic AnnuliPivotal-lookingNot yet recruiting
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT07794306 · 510 participants (planned) · Start Oct 26, 2026 · Primary completion Jul 31, 2028
Device: Meril Octapro+ THV System; Abbott Navitor/Navitor Vision THV system · For: Aortic Valve Stenosis
Sites: Hamburg, Germany
7 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Navitor", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NPT
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Navitor"[tiab]. The summary above synthesizes these.
- A Comprehensive Evaluation of the NAVITOR Transcatheter Aortic Valve Replacement System.
Aoun J, Zaid S, Goel S, et al. · Heart Int · 2024Review
- 30-Day and 1-Year Outcomes of Navitor Transcatheter Aortic Valve in Low- or Intermediate-Risk Patients.
Worthley SG, Giordano A, Corcione N, et al. · JACC Cardiovasc Interv · 2025Clinical Trial, Multicenter Study
- Ideal Navitor Implant Depth for Redo-TAVR Feasibility and Coronary Access: A CT Simulation Study.
Khera S, Zaid S, Krishnamoorthy P, et al. · JACC Adv · 2025
- Transcatheter Aortic Valve Replacement With the Navitor System: Real-World United Kingdom Experience.
Bharucha AH, Kanyal R, Mullen M, et al. · Am J Cardiol · 2024Multicenter Study
- SAPIEN3 Ultra RESILIA versus NAVITOR valve system in patients with a small aortic annulus: Insights from the OCEAN-TAVI Registry.
Mizutani K, Yamamoto M, Hioki H, et al. · Cardiovasc Revasc Med · 2026Comparative Study, Multicenter Study
- Predictors and Trends of New Permanent Pacemaker Implantation: A Subanalysis of the International Navitor IDE Study.
Sultan I, Reardon MJ, Søndergaard L, et al. · Struct Heart · 2024
- Navitor valve - a new TAVI solution for patients with aortic stenosis.
Grygier M, Olasiska-Wiśniewska A, Misterski M, et al. · Kardiol Pol · 2021
- How Does the TAVR Universe Best Expand?
Goel SS, Reardon MJ · JACC Cardiovasc Interv · 2025Editorial
- First-in-human TAVR With Navitor Self-expanding Intra-annular Valve in LVAD-Associated Aortic Regurgitation.
Guddeti RR, Garcia S, Egnaczyk GF, et al. · J Soc Cardiovasc Angiogr Interv · 2025
- Re-sheathing failure with Navitor during transcatheter aortic valve implantation: a case report.
Onoda H, Ueno H, Hida Y, et al. · Eur Heart J Case Rep · 2025Case Reports
- Intraprocedural assessment of commissural alignment of the Navitor system using the en-face view.
Hirose S, Nakashima M, Enta Y, et al. · Cardiovasc Interv Ther · 2023
- The Coronary Access After TAVI (CAvEAT) Study: A Prospective Registry of CA After TAVR.
Tarantini G, Nai Fovino L, Belloni F, et al. · JACC Cardiovasc Interv · 2025Multicenter Study, Comparative Study
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
- LOTUS Edge Valve SystemBoston Scientific Corporation · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.